Study of the complexation behavior of tenoxicam with cyclodextrins in solution: Improved solubility and percutaneous permeability

被引:21
作者
Larrucea, E [1 ]
Arellano, A [1 ]
Santoyo, S [1 ]
Ygartua, P [1 ]
机构
[1] Univ Navarra, Fac Farm, Dept Farm & Tecnol Farmaceut, E-31080 Pamplona, Spain
关键词
cyclodextrins; partitioning coefficient; percutaneous penetration; skin retention; stability constant; tenoxicam;
D O I
10.1081/DDC-120002840
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Complexation of tenoxicam (TEN) with gamma-, HPgamma-, beta-, HPbeta-, and Mbeta-cyclodextrin (CD) in aqueous solution at pH 7.4 has been investigated using phase solubility diagrams. TEN formed soluble complexes with 1:1 stoichiometry with all the CDs studied, although the inclusion stability constants (K-1.1) obtained had low values. The presence of propylene glycol (PG) in the dissolution medium decreased the stability constants and led to a higher fraction of free drug by competitive displacement and by an increase in the lipophility of the media. Among the CDs tested, MbetaCD was chosen for further studies since TEN-MbetaCD complexes yielded the best results: good solubility and the highest stability constant. The effect of MbetaCD and PG on the TEN partitioning coefficient was also studied in skin-buffer systems. Although each substance reduced the partitioning value, the combination of PG and MbetaCD increased this parameter. The noticeable increase in solubility of the drug found in the presence of MbetaCD allowed the formulation of carbopol gels with higher doses of TEN and a reduced amount of cosolvent. The presence of MbetaCD improved the percutaneous penetration of TEN through abdominal rat skin by increasing the solubility of the drug in the vehicle and by affecting the partitioning behavior of TEN in the skin. In addition, TEN retention in the skin was found to be related to the flux values attained with the corresponding gels.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 29 条
[1]  
Arima H, 1996, CHEM PHARM BULL, V44, P582
[2]   CYCLODEXTRINS IN THE PHARMACEUTICAL FIELD [J].
BEKERS, O ;
UIJTENDAAL, EV ;
BEIJNEN, JH ;
BULT, A ;
UNDERBERG, WJM .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (11) :1503-1549
[3]   Determination of the stability constant for the inclusion complex between beta-cyclodextrin and nicotine using capillary electrophoresis [J].
Berglund, J ;
Cedergren, L ;
Andersson, SB .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 156 (02) :195-200
[4]  
Duchene D, 1999, PROCEEDINGS OF THE 9TH INTERNATIONAL SYMPOSIUM ON CYCLODEXTRINS, P239
[5]  
Duchene D, 1996, POLYSACCHARIDES MED, P575
[6]  
GUENTERT TW, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1051
[7]  
Higuchi T., 1965, Interscience, New York, V4, P117
[8]   ANALYSIS OF DATA ON MEDICAMENT RELEASE FROM OINTMENTS [J].
HIGUCHI, WI .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1962, 51 (08) :802-&
[9]   Pharmaceutical applications of cyclodextrins .3. Toxicological issues and safety evaluation [J].
Irie, T ;
Uekama, K .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (02) :147-162
[10]   Transdermal delivery of naloxone: ex vivo permeation studies [J].
Jaiswal, J ;
Poduri, R ;
Panchagnula, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 179 (01) :129-134